Once-weekly semaglutide (marketed as Ozempic®), Novo Nordisk’s latest innovation in diabetes medication, helps manage blood sugar and body weight, and reduces the risk of heart problems, for people living with type 2 diabetes1-5 Novo.
Nordisk, a global pharmaceutical company specialized in diabetes, announced that once-weekly Ozempic® for the treatment of type 2 diabetes, is now available in Egypt. Alongside diet and exercise, Ozempic® can either be used alone or in addition to other products for diabetes management.
As mentioned by Dr. Hesham El Hefnawy Professor of diabetes and endocrinology Ex-Dean of National institute of Diabetes, Head of national non-communicable diseases committee “Type 2 diabetes is a complex disease. It develops when a person’s body cannot effectively use, or cannot make enough insulin, which helps regulate how much sugar is in the blood. Without insulin, too much sugar stays in the bloodstream where it can cause damage to vital organs and result in serious health problems.7 “.
“I see many people in my clinic each week with uncontrolled diabetes; in fact, nearly half the people living with type 2 diabetes do not have their condition in control, and are at risk of serious complications, such as cardiovascular disease, kidney diseases, retinopathy and neuropathy” said Professor Yehia Ghanem Professor of Diabetes and metabolism – Alexandria University “.
"With its superior and unique clinical profile, we believe that Ozempic® has the potential to set a completely new standard for treatment of type 2 diabetes. Due to its outstanding clinical benefits As well as reduction of cardiovascular diseases risk by 26%” When the condition is well managed, the risk of life-limiting and potentially fatal complications can be reduced. Said professor Samir George Professor of internal medicine and diabetes, Cairo University.
“Ozempic® is available in Egypt following of a series of clinical trials involving over 10,000 adults with type 2 diabetes. The results consistently showed greater reductions in both blood sugar and body weight compared with commonly used treatments for type 2 diabetes, as well as cardiovascular benefits, in people with type 2 diabetes.” elaborated professor Abbas Oraby, Professor of Diabetes and Endocrinology, Zagazig University.
“We are committed to developing new medicines for people living with diabetes and are delighted that Ozempic® is now available in Egypt,” said Ayman Hassan, Vice President and General Manager for Novo Nordisk. “As a once-weekly treatment which shows a remarkable ability to lower blood sugar, as well as reductions in body weight of up to 6.5 kg and a significant reduction in the risk of cardiovascular events such as stroke and heart attack, we believe Ozempic® will help meet the real and serious needs of those living with this condition.”
-Ends-
© Press Release 2021
Disclaimer: The contents of this press release was provided from an external third party provider. This website is not responsible for, and does not control, such external content. This content is provided on an “as is” and “as available” basis and has not been edited in any way. Neither this website nor our affiliates guarantee the accuracy of or endorse the views or opinions expressed in this press release.
The press release is provided for informational purposes only. The content does not provide tax, legal or investment advice or opinion regarding the suitability, value or profitability of any particular security, portfolio or investment strategy. Neither this website nor our affiliates shall be liable for any errors or inaccuracies in the content, or for any actions taken by you in reliance thereon. You expressly agree that your use of the information within this article is at your sole risk.
To the fullest extent permitted by applicable law, this website, its parent company, its subsidiaries, its affiliates and the respective shareholders, directors, officers, employees, agents, advertisers, content providers and licensors will not be liable (jointly or severally) to you for any direct, indirect, consequential, special, incidental, punitive or exemplary damages, including without limitation, lost profits, lost savings and lost revenues, whether in negligence, tort, contract or any other theory of liability, even if the parties have been advised of the possibility or could have foreseen any such damages.
